UBS cuts Waystar stock price target on guidance cadence update By Investing.com

Waystar reported Q1 2026 revenue of $314 million, slightly above the $313.9 million estimate, with adjusted EBITDA margin at 43% and EPS of $0.22. Management left FY2026 guidance unchanged but flagged near-term slowing, with Q2 expected roughly flat sequentially and Q3 growth of 1% to 3%, prompting UBS to cut its price target to $37 from $41 while keeping a Buy rating. Goldman Sachs also lowered its target to $33 from $38, reflecting a cautious analyst tone despite solid fundamentals.

Analysis

The key market signal is not the beat itself, but the guide cadence reset: management is implicitly trading near-term visibility for preserve-the-year confidence. That usually compresses the multiple first, then becomes a setup for a re-rate only if the next print re-accelerates; for a software-like compounder, the market tends to punish any sign that quarterly linearity is weakening even when EBITDA margins remain elite. The analyst downgrades in targets look more like a valuation reset than a fundamental thesis break, which means the downside is likely driven by multiple contraction rather than earnings cuts.

Second-order, this is a quality-vs-growth split inside the same name: healthy margins and decent organic growth support the long-term bull case, but the market will now focus on whether subscription mix can keep offsetting slower sequential activity. If second quarter comes in merely flat and the third quarter is only low-single-digit growth, the risk is that FY26 becomes a “show me” year, which can stall momentum investors and reduce the probability of multiple expansion until late in the cycle. That creates a window where the stock can look cheap on fundamental screens yet remain a dead money long for several months.

The contrarian take is that the Street may be overreacting to a normalizing cadence after an unusually strong execution streak. If the company keeps margins above the 40% target while guidance stays intact, the eventual buyer is likely to be a quality-growth fund that waited for a de-rating, not a fast-money dip buyer. In that sense, the setback is more about timing than thesis, and the real catalyst is not the next quarter alone but evidence that flat Q2 still leaves the full-year plan reachable without incremental concessions.

Key Decisions for Investors

• Do not add aggressively ahead of the next quarter; wait for post-print confirmation that sequential growth is stabilizing, because the near-term setup favors multiple compression over estimate upside.
• If already long WAY, hedge into the next 2-6 weeks with a short-dated call spread sale or collar; the risk/reward is skewed toward another guidance-driven de-rating rather than a quick rerate.
• For a relative-value expression, go long a high-quality healthcare workflow/software name with steadier quarterly cadence and short WAY for 1-3 months; the trade is a dispersion bet on consistency vs. decelerating linearity.
• Use a staggered entry only if the stock trades closer to the low-$20s and the company reiterates FY26 with no further downside to margin; that offers better asymmetry than buying the current post-earnings optimism.
• Monitor the next quarter for subscription mix and EBITDA margin durability; if margin holds while revenue cadence stays flat, the stock becomes a longer-duration recovery trade rather than a momentum long.